Call for a dedicated European legal framework for bacteriophage therapy
- PMID: 24500660
- PMCID: PMC3950567
- DOI: 10.1007/s00005-014-0269-y
Call for a dedicated European legal framework for bacteriophage therapy
Abstract
The worldwide emergence of antibiotic resistances and the drying up of the antibiotic pipeline have spurred a search for alternative or complementary antibacterial therapies. Bacteriophages are bacterial viruses that have been used for almost a century to combat bacterial infections, particularly in Poland and the former Soviet Union. The antibiotic crisis has triggered a renewed clinical and agricultural interest in bacteriophages. This, combined with new scientific insights, has pushed bacteriophages to the forefront of the search for new approaches to fighting bacterial infections. But before bacteriophage therapy can be introduced into clinical practice in the European Union, several challenges must be overcome. One of these is the conceptualization and classification of bacteriophage therapy itself and the extent to which it constitutes a human medicinal product regulated under the European Human Code for Medicines (Directive 2001/83/EC). Can therapeutic products containing natural bacteriophages be categorized under the current European regulatory framework, or should this framework be adapted? Various actors in the field have discussed the need for an adapted (or entirely new) regulatory framework for the reintroduction of bacteriophage therapy in Europe. This led to the identification of several characteristics specific to natural bacteriophages that should be taken into consideration by regulators when evaluating bacteriophage therapy. One important consideration is whether bacteriophage therapy development occurs on an industrial scale or a hospital-based, patient-specific scale. More suitable regulatory standards may create opportunities to improve insights into this promising therapeutic approach. In light of this, we argue for the creation of a new, dedicated European regulatory framework for bacteriophage therapy.
Figures
Similar articles
-
Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.Arch Immunol Ther Exp (Warsz). 2012 Jun;60(3):161-72. doi: 10.1007/s00005-012-0175-0. Epub 2012 Apr 17. Arch Immunol Ther Exp (Warsz). 2012. PMID: 22527355 Review.
-
Taking bacteriophage therapy seriously: a moral argument.Biomed Res Int. 2014;2014:621316. doi: 10.1155/2014/621316. Epub 2014 Apr 29. Biomed Res Int. 2014. PMID: 24868534 Free PMC article.
-
Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.FEMS Microbiol Lett. 2016 Feb;363(4):fnv241. doi: 10.1093/femsle/fnv241. Epub 2015 Dec 16. FEMS Microbiol Lett. 2016. PMID: 26678555
-
Bacteriophage applications: where are we now?Lett Appl Microbiol. 2010 Oct;51(4):363-9. doi: 10.1111/j.1472-765X.2010.02916.x. Epub 2010 Aug 26. Lett Appl Microbiol. 2010. PMID: 20796209
-
European regulatory aspects of phage therapy: magistral phage preparations.Curr Opin Virol. 2022 Feb;52:24-29. doi: 10.1016/j.coviro.2021.11.005. Epub 2021 Nov 23. Curr Opin Virol. 2022. PMID: 34801778 Review.
Cited by
-
Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections.Heliyon. 2024 Jul 18;10(14):e34849. doi: 10.1016/j.heliyon.2024.e34849. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39148970 Free PMC article. Review.
-
Exploring the Impact of Airway Microbiome on Asthma Morbidity: A Focus on the "Constructing a 'Eubiosis Reinstatement Therapy' for Asthma-CURE" Project.Pulm Ther. 2024 Jun;10(2):171-182. doi: 10.1007/s41030-024-00261-3. Epub 2024 May 30. Pulm Ther. 2024. PMID: 38814533 Free PMC article. Review.
-
The Medicinal Phage-Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation.Viruses. 2024 Mar 12;16(3):443. doi: 10.3390/v16030443. Viruses. 2024. PMID: 38543808 Free PMC article.
-
Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and Pseudomonas aeruginosa.BMJ Open Respir Res. 2023 May;10(1):e001360. doi: 10.1136/bmjresp-2022-001360. BMJ Open Respir Res. 2023. PMID: 37160359 Free PMC article.
-
The applications of animal models in phage therapy: An update.Hum Vaccin Immunother. 2023 Dec 31;19(1):2175519. doi: 10.1080/21645515.2023.2175519. Epub 2023 Mar 19. Hum Vaccin Immunother. 2023. PMID: 36935353 Free PMC article. Review.
References
-
- Caplin J. Bacteriophage: old treatment, new focus? Microbiologist. 2009;10:20–23.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous